Closing Remarks Speakers

Kelvin Lee, M.D.

Associate Dean of Cancer Research
Director, Indiana University Melvin and Bren Simon Comprehensive Cancer Center
H.H. Gregg Professor of Oncology
Professor of Medicine
Professor of Microbiology & Immunology
Indiana University School of Medicine

Kelvin Lee, MD, a world-recognized medical oncologist and multiple myeloma researcher, is director of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center. He is also associate dean of cancer research, H.H. Gregg Professor of Oncology, and professor of medicine and microbiology and immunology at IU School of Medicine. In addition, he is a physician at IU Health.

Previously, Lee was the Jacobs Family Chair of Immunology, a professor of medicine, vice chair of medicine, and senior vice president of basic sciences at Roswell Park Comprehensive Cancer Center in Buffalo, N.Y. It was at Roswell Park where he led America’s groundbreaking collaboration with cancer researchers in Cuba, who have developed a lung cancer vaccine that Roswell is testing in clinical trials.

An immunology expert, Lee is the principal investigator on multiple myeloma clinical trials, he holds two patents, and he has authored more than 100 papers in peer-reviewed journals.

 

Hari Nakshatri, Ph.D.

Marian J. Morrison Professor of Breast Cancer Research, Department of Surgery, Indiana University School of Medicine
Associate Director of Education, IU Simon Comprehensive Cancer Center

Dr. Nakshatri’s laboratory research interests are on heterogeneity in normal breast, the mechanisms of anti-estrogen resistance and metastasis in breast cancer. Ongoing research in his lab includes elucidating the mechanisms by which the serine/threonine kinase AKT alters estrogen signaling and confers anti-estrogen resistance in breast Cancer. One of the projects focuses on how loss of Dependence Receptor UNC5A leads to anti-estrogen resistance and metastasis of estrogen receptor positive breast cancer. His laboratory has identified and commercialized biomarkers that may predict response to anti-estrogen therapy. His laboratory was the first to demonstrate constitutive activation of NF-kappaB in a subset of breast cancer. Activated NF-kappaB confers chemotherapy resistance and enhances metastasis. An inhibitor of NF-kappaB developed by his lab in collaboration with other institutions is currently in phase I clinical trial for cancer. His laboratory is also investigating the mechanisms of organ-specific metastasis and the role of cancer stem cells in chemoresistance and metastasis. Using the normal breast tissue from Susan G. Komen for the Cure Tissue Bank, his group has shown ethnicity-dependent and ethnicity-independent heterogeneity in the normal breast. His group has also established a culturing method to grow tumors, and tumor adjacent-normal, and metastasis to genomically characterize tumors/metastasis at single cell level. NIH, Department of Defense, American Cancer Society, Susan G. Komen for Cure, Department of Veterans Affairs and other private foundations funded his research. He is the author or co-author of >130 publications with >14,000 citations. He has served/serving in scientific review committees of NIH, Department of Defense, Italian Association for Cancer Research, and Susan G. Komen for Cure. He is currently a member of the NIH Cancer Molecular Pathobiology Study Section. He is also in the editorial boards of scientific journals and an Associate Editor of Cancer Research, a premier journal from American Association for Cancer Research and Associate Editor-in-Chief of Cancer Management and Research. He has trained over 20 post-doctoral fellows, surgical residents, and medical students. In his role as the Associate Director of Education at the Indiana University Simon Cancer Center (IUSCC), he is responsible for developing educational activities of the cancer center and a training program in cancer biology.